However, the 2013 SAVOR-TIMI 53 trial reported that saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was non-inferior to placebo in cardiovascular safety but increased hospitalization for HF [127]. This evidence concerns the gene DPP4 and hydrops fetalis.